Michelle Branham, Florida's Secretary of Elder Affairs, is advocating for significant policy changes to accelerate the diagnosis of Alzheimer's disease and ensure wider access to newly developed treatments. Branham's personal experience losing her grandmother to vascular dementia in Queens, New York, has fueled her dedication to this cause.
In 2006, Branham's grandmother was diagnosed with vascular dementia, a condition that gradually diminished her vibrant personality and engagement with her family. After nearly a decade living with the disease, she passed away in 2016. This profound loss motivated Branham to join the Alzheimer's Association in 2012, where she served as vice president of public policy, fighting for improved policies for patients, families, and caregivers.
Advancing Research and the Need for Access
For years, the primary challenge in combating Alzheimer's and related dementias was the limited progress in research, leading to a lack of effective treatments. Branham joined other experts in calling for increased funding for Alzheimer's research and advocating for better policies. "What they needed was more research into Alzheimer’s and related dementias that yielded better care options," she stated.
Recent years have seen significant breakthroughs, including the development of the first treatments shown to slow cognitive decline in early-stage Alzheimer's. Furthermore, new blood tests are emerging that can identify biological markers of the disease years before symptoms become apparent, potentially enabling earlier diagnosis.
Policy Recommendations for Early Detection
Despite these scientific advancements, a major hurdle remains: ensuring patient access to these innovations. Branham, now leading efforts to serve older Floridians and their caregivers and chairing the federal Advisory Council on Alzheimer's Research, Care, and Services, has overseen the development of practical policy recommendations. These aim to accelerate innovation while ensuring that advances reach patients in need.
A critical area of focus is improving diagnostic timelines. Currently, Americans wait an average of three and a half years for a dementia diagnosis, by which time significant cognitive decline may have already occurred, limiting the effectiveness of interventions.
Branham advocates for modernizing cognitive assessment. She recommends that Medicare require standardized, validated cognitive assessment tools during initial and annual wellness visits for all older Americans. This would establish a consistent evaluation process to detect early signs of decline, as current assessments vary widely, allowing early indicators of dementia to be missed during the crucial window for intervention.
Additionally, Branham urges Congress to pass the ASAP Act without delay. This legislation would enable Medicare to cover U.S. Food and Drug Administration-approved Alzheimer's diagnostic tests for eligible patients, thereby facilitating quicker access to tests that can help confirm a diagnosis while there is still time to act.
"For the first time in decades, better options are here. Now, our policies must catch up," Branham stated, emphasizing the urgent need for policy to align with scientific progress to provide more meaningful time for patients and their families.